FDA approves Boehringer Ingelheim’s Gilotrif for squamous cell lung cancer

SILVER SPRING, Md. — The Food and Drug Administration recently approved Boehringer Ingelheim Pharmaceuticals’ Gilotrif, a treatment for patients with advanced squamous cell carcinoma of the lung whose illness has progressed following platinum-based chemotherapy. 

 

The once-daily oral therapy had previously been approved as a first-line treatment for specific types of non-small cell lung cancer. 

 

“We are pleased to bring a proven therapy to patients suffering from advanced squamous cell carcinoma of the lung who have progressed despite chemotherapy,” Boehringer Ingelheim said Sabine Luik, MD, senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "This approval is further evidence of Boehringer Ingelheim's strong commitment to bringing new treatment options to the lung cancer community."